- Drugs List
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Each 2.2ml cartridge contains 66mg of mepivacaine hydrochloride solution for injection.
2.2ml (66mg) mepivacaine 3% injection for routine work. Maximum of 6.6ml (198mg) mepivacaine 3% injection should not be exceeded.
2.2ml (66mg) to 4ml (120mg) mepivacaine 3% injection . Use no more than 4.4ml (132mg) mepivacaine 3% injection per digit. Maximum of 6mg/kg bodyweight in 24 hours should not be exceeded.
Elderly patients should be given reduced doses commensurate with their age and physical condition.
For children from age 4 the quantity to be injected should be determined by the age, weight of the child and magnitude of the procedure being undertaken.
The average dosage is 0.75mg/kg which is equal to 0.025ml/kg of mepivacaine solution.
Do not exceed 3mg/kg or 0.1ml/kg of body weight.
Patients with Renal Impairment
Use with caution as mepivacaine is excreted by the kidneys.
Patients with renal disease are at a greater risk of developing toxic plasma concentrations.
Patients with Hepatic Impairment
Use with caution as mepivacaine is metabolised by the liver.
Patients with severe hepatic disease are at a greater risk of developing toxic plasma concentrations.
Additional Dosage Information
Onset of action is 30 to 120 seconds in the upper jaw and 1 to 4 minutes in the lower jaw.
Mepivacaine produces an operative anaesthesia of 20 minutes in the upper jaw and 40 minutes in the lower jaw.
Onset of action is between 4 and 8 minutes, and an operative anaesthesia of approximately 1 hour is produced.
For dental or subcutaneous injection.
Children under 4 years
Precautions and Warnings
Mepivacaine must be administered by a specialist who is aware of the diagnosis and management of emergencies arising from the use of anaesthesia. Resuscitative equipment and facilities should be immediately available when local anaesthetics are administered.
After administration, cardiovascular and respiratory vital signs and the patient's state of consciousness should be monitored. Possible central nervous system toxicity may be indicated by restlessness, anxiety, tinnitus, dizziness, blurred vision, tremors, depression or drowsiness. Signs of cardiovascular depression may result from a vasovagal reaction, especially if the patient is in an upright position. If an adverse reaction is noted the patient should be placed in a recumbent position.
For dental or subcutaneous injection only. To minimise the risk of intravascular injection, double aspiration should be performed before mepivacaine is injected. Note that the absence of blood in the syringe does not assure that intravascular injection will be avoided.
Mepivacaine should be used with caution if there is inflammation or infection at the site of the proposed injection. This may alter the pH at the site of injection and reduce the anaesthetic effect.
Debilitated patients, elderly and children should be given lower doses commensurate with their age and physical condition.
Patients with hepatic impairment should be treated with caution as mepivacaine is metabolised by the liver. Patients with severe hepatic disease are at a greater risk of developing toxic plasma concentrations.
Patients with renal impairment should be treated with caution as mepivacaine is excreted by the kidneys, and they consequently have a greater risk of developing toxic plasma concentrations.
Carefully consider the use of mepivacaine in patients with a history of severe disturbance of cardiac rhythm or heart block. In these patients, the depressant cardiac effects of mepivacaine may be detrimental to the patient.
Pregnancy - see Pregnancy section.
Breastfeeding- see Lactation section.
Pregnancy and Lactation
Mepivacaine-type anaesthetics are considered safe for use during pregnancy based on their long usage. However caution should be exercised during early pregnancy as no controlled studies have been carried out in pregnant women.
Retrospective studies of pregnant women who were given local anaesthesia during the early stages of pregnancy have not shown any evidence of birth defects.
No animal reproduction studies have been performed with mepivacaine.
The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14-17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Caution should be exercised when mepivacaine is administered during lactation.
It is not known if mepivacaine is excreted in human milk.
Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
Specialist advice is available from the UK Drugs in Lactation Advisory Service at https://www.midlandsmedicines.nhs.uk/content.asp?section=6&subsection=17&pageIdx=1
Sensation of heat
Sensation of cold
Changes in pulse
Changes in cognitive and sensorial capacity
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Shelf Life and Storage
Store below 25 degrees C.
Protect from light.
Keep the container in the outer carton.
If only part of the cartridge is used, the rest must be discarded.
Last Full Review Date: August 2011
British National Formulary, 61st Edition (2011) Pharmaceutical Press, London.
Martindale: The Complete Drug Reference, 37th edition (2011) ed. Sweetman, S. Pharmaceutical Press, London.
Summary of Product Characteristics: Scandonest 3% Plain. Septodont Ltd. Revised February 2011.
US National Library of Medicine. Toxicology Data Network. Drugs and Lactation Database (LactMed).
Available at: https://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT
Mepivacaine. Last revised: April, 02 2009
Last accessed: June, 07 2011
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.